SAN DIEGO and TORONTO, Aug. 15, 2024 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced that its special meeting of shareholders (the “Meeting”) convened on August 15, 2024, at 1:00 p.m. (ET) […]
Category Archives: Pr Newswire
Pr Newswire
Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024
16
Aug
Aug
Record Total Revenues of $236 million for the first six months of 2024, an over ten-fold increase compared to same period in 2023 Product revenues for the first six months were $66 million, a 190% increase from the same period last year, with Q2 product revenues contributing $53 million License and other revenues for the […]
Pr Newswire
Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024
16
Aug
Aug
Record Total Revenues of $236 million for the first six months of 2024, an over ten-fold increase compared to same period in 2023 Product revenues for the first six months were $66 million, a 190% increase from the same period last year, with Q2 product revenues contributing $53 million License and other revenues for the […]
NORFOLK, Va., Aug. 16, 2024 /PRNewswire/ — PRA Group, Inc. (Nasdaq: PRAA), a global financial services company, is proud to announce Elizabeth Kersey, senior vice president of communications and public policy, was named the winner of a Silver Stevie® Award in the Communications, Investor Relations or PR Executive of the Year category in the 21st Annual International […]
TORONTO, Aug. 16, 2024 /PRNewswire/ — Visionary Holdings Inc. (the “Company”) (NASDAQ:GV), a private education provider located in Canada, with subsidiaries in Canada and market partners in China, today announced its financial results for the fiscal year ended March 31, 2024. Fiscal Year 2024 Financial Highlights Revenues increased by $0.9 million, or 11.2%, to approximately $9.4 […]
SHANGHAI, Aug. 16, 2024 /PRNewswire/ — On August 16, 2024 (local time), Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. officially announced the launch of the “Sanyou Innovative Intelligent Antibody Design oneClick+ Platform.” Sanyou Bio’s Innovative Intelligent Antibody Design oneClick+ Platform, independently designed by Sanyou Bio, integrates 90% of the mainstream antibody structures currently available on the market and […]
LOS ANGELES, Aug. 16, 2024 /PRNewswire/ — Prime Focus Technologies (PFT), a pioneer in AI-powered technology solutions, unveils CLEAR® AI Agents at IBC 2024 in Amsterdam. These are designed to assist & co-work with professionals within Media & Entertainment (M&E) enterprises to execute specific tasks across content management, postproduction, and marketing. The agents seamlessly handle repetitive tasks, […]
SHANGHAI, Aug. 16, 2024 /PRNewswire/ — XChange TEC.INC (NASDAQ: XHG) (the “Company”), today announced that it received two letters, dated August 12 and 14, 2024, respectively, from The Nasdaq Stock Market (“Nasdaq”) notifying the Company that it had regained compliance with the requirement to maintain a minimum bid price of $1 per share as set […]
Pr Newswire
Pathos Expands Pipeline With Worldwide License of Phase 2-ready Brain-penetrant, PRMT5 Inhibitor
15
Aug
Aug
CHICAGO, Aug. 15, 2024 (GLOBE NEWSWIRE) — Pathos AI, Inc. (www.pathos.com), a biotechnology company focused on revolutionizing precision medicine in cancer by harnessing the power of machine learning to transform drug development, announced today the world-wide license of PRT811, a potent, selective, and orally bioavailable brain penetrant SAM-competitive PRMT5 inhibitor from Prelude Therapeutics. PRT811 (renamed […]
Pr Newswire
DiagnaMed Offering its Brain Health AI Platform for Investigating Weight Loss Drugs, such as Semaglutide (GLP-1), on Brain Function
15
Aug
Aug
TORONTO, Aug. 15, 2024 (GLOBE NEWSWIRE) — DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a healthcare technology company focused on brain health using AI, is offering its novel BRAIN AGE® Brain Health AI Platform (“BRAIN AGE®”) as a clinical tool for investigating the impact of weight loss drugs, such as Semaglutide, […]